ADVFN - Advanced Financial Network.
HOME» NASDAQ » H » HGSI Stock Price » HGSI Stock News

Human Genome Sciences Share News

 Human Genome Sciences (mm) Stock Price
HGSI Stock Price
 Human Genome Sciences (mm) Stock Chart
HGSI Stock Chart
 Human Genome Sciences (mm) Stock News
HGSI Stock News
 Human Genome Sciences (mm) Company Information
HGSI Company Information
 Human Genome Sciences (mm) Stock Trades
HGSI Stock Trades

Glaxo, Human Genome Sciences Initiate Phase III Trial Of Belimumab

LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK.LN) and Human Genome Sciences (HGSI) Thursday announced that dosing has been initiated in BLISS-SC, a new Phase III trial to evaluate the efficacy, safety and tolerability of BENLYSTA administered subcutaneously once-weekly to autoantibody-positive adults with active systemic lupus erythematosus, or SLE. MAIN FACTS: -Study to enrol over 800 adult patients with SLE -Will evaluate once-weekly subcutaneous injections of an investigational formulation of belimumab plus standard of care vs. placebo plus standard of care -GlaxoSmithKline shares at 1210 GMT up 1.32% at GBP14.6 valuing the company at GBP73.5 billion. -By Jana Weigand, Dow Jones Newswires; 44-20-7842-9314;

Stock News for Human Genome Sciences (HGSI)
No Recent News Available

Human Genome Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations